Skip to main content
. 2017 Dec 8;2017(1):79–87. doi: 10.1182/asheducation-2017.1.79

Table 2.

Laboratory screening tests and hematologic features of the IBMFSs organized by typical first presenting cytopenia

Macrocytosis
Thrombocytopenia Anemia Neutropenia
TAR TBD FA DBA SDS GATA2 deficiency SCN
Screening test Arm X-ray Decreased lymphocyte telomere lengths Spontaneous and DEB/MMC-induced chromosome breaks and radial configurations Elevated red cell adenosine deaminase Decreased pancreatic isoamylase and/or trypsinogen Increased FLT3 ligand None
Peripheral blood Normal-size platelets Normal-size platelets, elevated hemoglobin F Normal-size platelets, elevated hemoglobin F Reticulocytopenia, elevated hemoglobin F B- and T-cell defects, elevated hemoglobin F, neutrophil chemotaxis defects Monocytopenia B and NK cell deficits, CD4:CD8 ratio <1
Pre-MDS/AML bone marrow findings Decreased megakaryocytes Hypocellular, evolving unilineage to trilineage dysplasia Hypocellular, erythroid dysplasia, cytogenetics: +1q, +3q* Normocellular, then hypocellular with age; decreased erythroid precursors Hypocellular, myeloid dysplasia, cytogenetics: del(20)(q 11), i(7)(q10) Hypocellular, megakaryocytic atypia, fibrosis Promyelocyte maturation arrest
MDS/AML subtype NA NA RCMD, RAEB, RARS, MDS-NOS NA Varied RCC or RAEB (children); RCMD, RAEB, CMML (adults) Varied
MDS/AML cytogenetics NA NA Unbalanced +1q, −7/–7q, +3q* NA Abnormal chromosome 7 Monosomy 7, trisomy 8, trisomy 21 Varied
MDS/AML acquired genetic features NA NA RUNX1* by large genomic events NA TP53 ASXL1 CSF3R, RUNX1

This table provides an overview of the most common laboratory screening tests and hematologic features of the IBMFSs (in bold); see detailed reviews for additional features.4,5,7,8,18,20,27,28,31,32,36,37,41,49-51

CMML, chronic myelomonocytic leukemia; DEB, diepoxybutane; MMC, mitomycin C; NA, not available; NK, natural killer; NOS, not otherwise specified; RAEB, refractory anemia with excess blasts; RARS, refractory anemia with ringed sideroblasts; RCC, refractory cytopenia of childhood; RCMD, refractory cytopenia with multilineage dysplasia.

*

Best detected by fluorescence in situ hybridization, array comparative genomic hybridization, or next-generation sequencing techniques because size is not usually detectable at the gross karyotypic level.